Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Rosafalco

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Thrombosis and Haemostasis|November 6, 2015
Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised studyJuan Jose Cerezo-Manchado, Vanessa Roldán, Javier Corral, et al.
Thrombosis and Haemostasis|December 1, 2012
Creating a genotype-based dosing algorithm for acenocoumarol steady doseJuan J Cerezo-Manchado, Mario Rosafalco, Ana I Antón, et al.
Pharmacogenomics|June 24, 2014
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatmentJuan Jose Cerezo-Manchado, Vanessa Roldan, Mario Rosafalco, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Thrombosis and Haemostasis|November 6, 2015
Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised studyJuan Jose Cerezo-Manchado, Vanessa Roldán, Javier Corral, et al.
Thrombosis and Haemostasis|December 1, 2012
Creating a genotype-based dosing algorithm for acenocoumarol steady doseJuan J Cerezo-Manchado, Mario Rosafalco, Ana I Antón, et al.
Pharmacogenomics|June 24, 2014
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatmentJuan Jose Cerezo-Manchado, Vanessa Roldan, Mario Rosafalco, et al.
Pageof 1